{"id":645789,"date":"2023-04-06T14:22:01","date_gmt":"2023-04-06T14:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=645789"},"modified":"2023-04-06T14:22:01","modified_gmt":"2023-04-06T14:22:01","slug":"lowgrade-serous-ovarian-carcinoma-market-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-states-delveinsight-key-companies-pfizer-context-therapeutics-merck","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lowgrade-serous-ovarian-carcinoma-market-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032-states-delveinsight-key-companies-pfizer-context-therapeutics-merck_645789.html","title":{"rendered":"Low-Grade Serous Ovarian Carcinoma Market Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Pfizer, Context Therapeutics, Merck"},"content":{"rendered":"
\n
\"Low-Grade<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Low-Grade Serous Ovarian Carcinoma (LGSOC) \u2014 Market Insights, Epidemiology, and Market Forecast \u2014 2032” report delivers an in-depth understanding of the Low-Grade Serous Ovarian Carcinoma, historical and forecasted epidemiology as well as the Low-Grade Serous Ovarian Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight’s “Low-Grade Serous Ovarian Carcinoma (LGSOC) — Market Insights, Epidemiology, and Market Forecast — 2032<\/a><\/strong>” report delivers an in-depth understanding of the Low-Grade Serous Ovarian Carcinoma, historical and forecasted epidemiology as well as the Low-Grade Serous Ovarian Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Low-Grade Serous Ovarian Carcinoma market report provides current treatment practices, emerging drugs, Low-Grade Serous Ovarian Carcinoma market share of the individual therapies, and current and forecasted Low-Grade Serous Ovarian Carcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Low-Grade Serous Ovarian Carcinoma treatment practice\/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.<\/p>\n

 Low-Grade Serous Ovarian Carcinoma Market Overview<\/strong><\/p>\n

Low-grade serous ovarian carcinoma (LGSOC) is an uncommon (<5%) and under-investigated ovarian cancer type, in some cases arising from serous borderline tumors. In contrast to high-grade serous ovarian cancers (HGSOCs), LGSOCs are TP53 wild-type, do not demonstrate genomic instability or homologous recombination repair deficiency, and frequently harbor classical activating mutations in canonical MAPK pathway components (KRAS, BRAF, and NRAS). LGSOCs typically display high estrogen receptor (ER) expression, with an expression of progesterone receptor (PR) in a subset of cases. Compared with the most common form of ovarian cancer, known as high-grade serous ovarian cancer like pain, bloating, difficulty eating, and bowel and urinary changes as pelvic and abdominal organs are gradually affected. It is thought to start in the ovaries or fallopian tubes and is usually at stages 2 to 4 when it is diagnosed, meaning that it has spread away from the fallopian tubes and ovaries into the pelvis and then the abdomen. <\/p>\n

\"\"<\/p>\n

Learn more about the Low-Grade Serous Ovarian Carcinoma  market @ Low-Grade Serous Ovarian Carcinoma Market Landscape<\/a><\/strong><\/p>\n

 Low-Grade Serous Ovarian Carcinoma Epidemiological Segmentation <\/strong><\/p>\n